Introduction of SGLT2 Inhibitors and Variations in Other Disease-Modifying Drugs in Heart Failure Patients: A Single-Centre Real-World Experience

Background: The sodium–glucose cotransporter-2 inhibitors (SGLT2i) have emerged as a crucial therapeutic option for patients with chronic heart failure with reduced ejection fraction (HFrEF). The aim of this study was to evaluate, in a real-world population from a single centre, the feasibility of i...

Descripción completa

Detalles Bibliográficos
Autores principales: Tabella, Erika, Correale, Michele, Alcidi, Gianmarco, Pugliese, Rosanna, Ioannoni, Sara, Romano, Matteo, Palmieri, Gianpaolo, Di Biase, Matteo, Brunetti, Natale Daniele, Iacoviello, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514827/
https://www.ncbi.nlm.nih.gov/pubmed/37736926
http://dx.doi.org/10.3390/clinpract13050090

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514827/
https://www.ncbi.nlm.nih.gov/pubmed/37736926
http://dx.doi.org/10.3390/clinpract13050090

Ejemplares similares